Lv1
30 积分 2024-02-18 加入
P3.18.59 Resistance Mechanisms and Sequential Therapies Following 1St Line Lorlatinib in ALK+ NSCLC: A Real-World Study (LORES CTONG2501)
11小时前
已完结
First-Line Therapy For Advanced Non–Clear Cell Renal Cell Carcinoma
1个月前
已完结
Comprehensive management strategies for amivantamab-induced toxicities and review of the literature
2个月前
已完结
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
2个月前
已完结
Advances in the management of endometrial cancer
4个月前
已完结
皖公网安备34019202002308
